PMID- 24394077
OWN - NLM
STAT- MEDLINE
DCOM- 20140310
LR  - 20151119
IS  - 0385-0684 (Print)
IS  - 0385-0684 (Linking)
VI  - 40
IP  - 12
DP  - 2013 Nov
TI  - [A case of SPT therapy( S-1+CDDP+trastuzumab) was successful for HER2-positive 
      gastric cancer accompanied by distant lymph node metastasis].
PG  - 2256-8
AB  - A 63-year-old man visited our clinic with a chief complaint of a left axillary 
      mass, and after a series of examinations, gastric cancer was diagnosed. 
      Histopathological examination revealed a human epidermal growth factor receptor 
      (HER)-2- positive( immunohistochemistry[ IHC], 2+; fluorescence in situ 
      hybridization[ FISH], positive) poorly differentiated adenocarcinoma, and SPT 
      therapy( S-1 at 120 mg/m2/day+cisplatin[ CDDP] at 60 mg/m2+trastuzumab at 8 
      mg/kg) was initiated. The primary lesion and swollen lymph nodes initially 
      decreased markedly in size; however, the lymph node swelling worsened at 186 
      days( 6.2 months) after the initiation of treatment. Progressive disease( PD) was 
      diagnosed, and SPT therapy was terminated. One cycle of S-1+docetaxel was 
      administered as second-line therapy, but the regimen was changed to docetaxel 
      monotherapy due to adverse effects. After 5 cycles of this treatment, the primary 
      lesion had decreased in size and the lymphadenopathy disappeared. Positron 
      emission tomography( PET)-computed tomography (CT) revealed fluorodeoxyglucose( 
      F18)( FDG) accumulation only in the primary lesion, and therefore, with the 
      patient's informed consent distal gastrectomy was performed approximately 14 
      months after the first treatment. The postoperative diagnosis was gastric cancer 
      fStage IA (T1a, N0, and M0). Here, we discuss a case of HER2-positive gastric 
      cancer with references. Among the advanced recurrent gastric cancers tested 
      between April 2011 and February 2013, 16.4% (11/67) were HER2-positive.
FAU - Hyuga, Nozomu
AU  - Hyuga N
AD  - Dept. of Surgery, Kinki Central Hospital.
FAU - Kobayashi, Kenji
AU  - Kobayashi K
FAU - Watanabe, Risa
AU  - Watanabe R
FAU - Chono, Akihiro
AU  - Chono A
FAU - Matsumoto, Takashi
AU  - Matsumoto T
FAU - Takemoto, Hiroyoshi
AU  - Takemoto H
FAU - Takachi, Ko
AU  - Takachi K
FAU - Nishioka, Kiyonori
AU  - Nishioka K
FAU - Aoki, Taro
AU  - Aoki T
FAU - Uemura, Yoshio
AU  - Uemura Y
FAU - Yoshida, Kyotaro
AU  - Yoshida K
LA  - jpn
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Gan To Kagaku Ryoho
JT  - Gan to kagaku ryoho. Cancer & chemotherapy
JID - 7810034
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Drug Combinations)
RN  - 150863-82-4 (S 1 (combination))
RN  - 1548R74NSZ (Tegafur)
RN  - 5VT6420TIG (Oxonic Acid)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Cisplatin/administration & dosage
MH  - Drug Combinations
MH  - Humans
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Oxonic Acid/administration & dosage
MH  - Receptor, ErbB-2/analysis
MH  - Stomach Neoplasms/chemistry/*drug therapy/pathology/surgery
MH  - Tegafur/administration & dosage
MH  - Trastuzumab
EDAT- 2014/01/08 06:00
MHDA- 2014/03/13 06:00
CRDT- 2014/01/08 06:00
PHST- 2014/01/08 06:00 [entrez]
PHST- 2014/01/08 06:00 [pubmed]
PHST- 2014/03/13 06:00 [medline]
PST - ppublish
SO  - Gan To Kagaku Ryoho. 2013 Nov;40(12):2256-8.